I. INTRODUCTION
Subsequent studies confirmed this classification of this receptor was demonstrated (91, 162, 315) . The D 3 receptor was identified by screening a rat cDNA library scheme, and D 1 and D 2 receptors were clearly differentiated pharmacologically, biochemically, physiologically, with the D 2 receptor sequence followed by PCR extension and genomic library screening (420). The D 4 receptor was and by their anatomic distribution.
Concurrently in the late 1970s, by means of functional cloned by screening a library from the human neuroblastoma cell line SK-N-MC (450). tests such as renal blood flow and cardiac acceleration measurements in the dog, the existence of specific peripheral The D 1 receptor was cloned by using either low-stringency screening of libraries or PCR based on the sequence receptors for DA was demonstrated. These receptors were named DA 1 and DA 2 on the basis of some pharmacological of the D 2 receptor (95, 314, 480) . The second member of the D 1 -like receptor family was isolated using the seproperties distinguishing them from their central counterparts (reviewed in Ref. 166) . This led to a long-standing quence of the D 1 receptor and was referred to as D 5 (431), D 1b (441) and D 1b (464) . It is now well established that controversy concerning the identity or nonidentity of peripheral versus central receptors. However, subsequent bio-the D 5 and D 1b are the human and rat equivalents of the same receptor. chemical and molecular biology studies in peripheral tissues pointed to extensive similarities between central and periph-
The genomic organization of the DA receptors supports the concept that they derive from the divergence of eral DA receptors so that the DA 1 /DA 2 classification has been dropped (reviewed in Refs. 7, 307, 326, 336) .
two gene families that mainly differ in the absence or the presence of introns in their coding sequences. As summaFor a decade, the dual receptor concept served as the foundation for the study of DA receptors. However, rized in Table 1 the gene for rhodopsin (327) , the genes encoding the D 2 -like receptors are interrupted by introns (reviewed in Detailed structural, pharmacological, and biochemical studies pointed out that all DA receptor subtypes fall Refs. 78, 159, 337 ). It appears likely that many of the genes in the G protein-coupled receptor family have arisen from into one of the two initially recognized receptor categories. The Analysis of the gene structure of D 2 -like receptors of signaling events, that is, positive and negative coupling to AC, appears to apply, in broad terms, also to the novel revealed that the D 2 receptor coding region contains six introns (91, 162, 168, 315) , the D 3 receptor coding region members of the DA receptor family, the D 5 /D 1b receptor being coupled to stimulation of AC (95, 169, 431, 441) and five (420), and the D 4 receptor three (450). Interestingly, the localization of introns is similar in the three receptor the D 3 (137, 161, 418). Analysis of the gene for the human D 4 in serine and threonine residues, and contains a cysteine receptor revealed the existence of polymorphic variations residue that is conserved in all G protein-coupled receptors within the coding sequence. A 48-bp sequence in the third and that has been shown to be palmitoylated in the bcytoplasmic loop exists either as a direct repeat sequence, adrenergic receptors and in rhodopsin probably to anchor as a fourfold repeat, or a sevenfold repeat. D 4 receptors the cytoplasmic tail to the membrane (338, 347). In the D 1 -containing up to 11 repeats have been found (451).
like receptors, this cysteine residue is located near the The D 5 receptor has two related pseudogenes on hu-beginning of the COOH terminus, whereas in the D 2 -like man chromosomes 1 and 2. They are 98% identical to each receptors, the COOH terminus ends with this cysteine resiother and 95% identical to the human D 5 receptor and code for truncated, nonfunctional forms of the D 5 receptor (169, 464) .
IV. STRUCTURE OF DOPAMINE RECEPTORS
Analysis of the primary structure of the cloned DA receptors revealed that they are members of the seven transmembrane (TM) domain G protein-coupled receptor family and share most of their structural characteristics (Fig. 1) . Members of this family display considerable amino acid sequence conservation within TM domains (reviewed in Ref. 362) .
Analysis of DA receptor structure pointed to similarities and dissimilarities between D 1 -like and D 2 -like receptors (78, 159, 217, 337) . Members of the same family share considerable homology. The D 1 and D 5 receptors share a 80% identity in their TM domains. The D 2 and D 3 receptors have a 75% identity in their TM domains, and the D 2 and D 4 receptors share a 53% identity in the TM domains.
The NH 2 -terminal stretch has a similar number of amino acids in all the receptor subtypes and carries a variable number of consensus N-glycosylation sites. The (Fig. 1) . Likewise, as in all G protein-coupled receptors, acids in the third intracellular loop (D 2S and D 2L ) (91, 162, 315) . Because this loop seems to play a central role in DA receptors possess two cysteine residues in extracellular loops 2 and 3 (reviewed in Refs. 78, 159, 217, 337) , which receptor coupling, the existence of a splicing mechanism at this level could imply functional diversity. However, in have been suggested to form an intramolecular disulfide bridge to stabilize the receptor structure (111, 142) . The spite of the efforts of several groups, no obvious differences have emerged so far between the two D 2 receptor D 2 -like receptors have a long third intracellular loop, a feature which is common to receptors interacting with G i isoforms. Both variants share the same distribution pattern, with the shorter form less abundantly transcribed proteins to inhibit AC, whereas the D 1 -like receptors are characterized by a short third loop as in many receptors (91, 162, 315, 328) . Both isoforms revealed the same pharmacological profile, even if a marginal difference in the coupled to G s protein (reviewed in Refs. 78, 159, 337) .
The D 1 and D 5 receptor third intracellular loop and affinity of some substituted benzamides has been reported (66, 278) . When expressed in host cell lines, both isoforms the COOH terminus are similar in size but divergent in their sequence. In contrast, the small cytoplasmic loops inhibited AC (91, 162, 315) . However, the D 2S receptor isoform displayed higher affinity than the D 2L in this effect 1 and 2 are highly conserved so that any difference in the biology of these receptors can be probably related to the (91, 317) . Both isoforms mediate a phosphatidylinositollinked mobilization of intracellular calcium in mouse Ltk 0 third cytoplasmic loop and the COOH-terminal tail (reviewed in Refs. 78, 159, 337) . The external loop between fibroblasts. Protein kinase C (PKC), however, differentially modulates D 2S -and D 2L -activated transmembrane TM4 and TM5 is considerably different in the two receptor subtypes, being shorter (27 amino acids) in the D 1 recep-signaling in this system with a selective inhibitory effect on the D 2S -mediated response (265) . Attempts to identify tor than in the D 5 receptor (41 amino acids). The amino acid sequence of this loop, in addition, is divergent in the the preferred G protein a-subunit for D 2S (189, 190, 443) suggested that the agonist binding port showed that in transfected cell lines the D 2S isoform signals preferentially through G i-2 a and the D 2L through likely occurs within the hydrophobic TM domains (Fig. 1) . Highly conserved residues are present in the core of the G i-3 a (405) . The two receptor variants, in addition, appear to differ in their mode of regulation (240, 283, 479) . protein and define a narrow binding pocket that most probably corresponds to the agonist binding site (190) . In particular, an aspartate residue in TM3 is most probably involved B. D 3 Receptor in binding the amine group of the catecholamine side chain (190, 427) . Two serine residues in TM5 have been shown
Splice variants of the D 3 receptor have also been identified. One transcript carries a 113-bp deletion in TM3 and to be hydrogen bond donors to bind the hydroxyl groups of the catechol moiety for the b 2 -(426), a 2 -(458), D 2 (85, a frame shift in the coding sequences generating a stop codon shortly after the deletion and encodes a 100-amino 282), and D 1 (442) receptors. A phenylalanine in TM6 is highly conserved in all receptors interacting with catechol-acid-long truncated form of the receptor (418). A second variant derives from a deletion of 54 bp between TM5 and amine neurotransmitters and can make a stabilizing orthogonal interaction with the aromatic moiety of the ligand. A TM6 of the D 3 receptor. Although this structure may be compatible with the occurrence of seven transmembrane highly conserved aspartate residue in TM2 has been shown to play a crucial role in b 2 -adrenergic (77, 190, 427), a 2 -domains, cell lines transfected with this cDNA failed to show any binding (161). Two alternatively spliced forms adrenergic (458), and D 1 (442) and D 2 dopaminergic (328) receptor activation and to affect agonist binding (190, 414 , of the D 3 receptors have been identified in the mouse (137), but not in other species (161). These differ by a 442). It has been suggested that the interaction between this aspartate and the agonist is allosteric and can be modu-stretch of 21 amino acids in the third intracellular loop and are generated by a splicing mechanism that uses an lated by Na / or H / (189, 196, 328) . A number of cytoplasmic residues, such as the DRY sequence in the second intracellu-internal acceptor site inside an exon, rather than a separate exon like the D 2 receptor. Both isoforms bind dopalar loop or the alanine residue in the third intracellular loop of the a-adrenoceptor, also play a role in receptor activation minergic ligands with a D 3 pharmacological profile and have the same distribution pattern with the longer form (233, 427 
it has been shown that although they bind hallmark D 2 -5 nM; //, 5 nM õ K i õ 50 nM; /, 50 nM õ K i õ 500 nM; //0, 500 nM õ K i õ 5 mM; 0, K i ú5 mM; ND, not determined; 7-OH-DPAT, 7-selective ligands with high affinity, nevertheless both of hydroxy-dipropylaminotetralin.
these receptors have distinguishing pharmacological characteristics (Table 2) . The pharmacological profile of the D 3 receptor rethe D 2 -like receptors. In human polymorphic variants, the veals that some agonists and antagonists can distinguish D 4 receptor exists with different insertions in the third it from the D 2 . Dopamine itself has 20 times higher affinity intracellular loop. This loop contains repeat sequences of at the D 3 than at the D 2 receptor (420), and this has been 16 amino acids with the number of repeats differing in related in part to their sequence differences in the third the different forms of the receptor. The four-repeat form intracellular loop (378) . Among agonists, although apo- (D 4.4 ) is the predominant in the human population (60%).
morphine and bromocriptine display similar affinities for The D 4.7 variant is present in 14% of the population and both receptors, TL-99, pergolide, quinpirole, and 7-hythe D 4.2 in 10% (401, 451) . Receptor forms with up to 10 droxy-dipropylaminotetralin (7-OH-DPAT) bind with repeats have also been identified but are much less frehigher affinity at the D 3 than at the D 2 . Quinpirole and 7-quent (401) . The functional significance of these variants OH-DPAT are the most discriminating compounds, with has not been elucidated. They display a slightly different affinities 100 and 10 times higher than at the D 2 , respecaffinity for the neuroleptic clozapine, but none of them tively (Table 2 ) (420). Most neuroleptics display nanomohas been related to an increased incidence of schizophrelar affinity at both receptors. However, haloperidol and nia (401, 451 3 but to a much lesser extent D 4 receptors. The difference in binding densities of these proteins. However, it has also been shown that G olf a, which also stimulates AC, is expressed in caudate, nutwo ligands has been proposed to reflect specific D 4 receptor binding (400) .
cleus accumbens, and olfactory tubercle and is more abundant in these tissues than G s a (188). This suggests that the D 1 receptor in particular, which is highly ex-VII. SIGNAL TRANSDUCTION OF pressed in these brain areas, may couple to AC by pre-DOPAMINE RECEPTORS viously unappreciated mechanisms. Recent studies suggested that D 1 -like receptors can also couple to G proteins The coupling of DA receptors to second messenger different from G s a. In particular, striatal D 1 receptors appathways has been a subject of intense interest ever since pear to be associated with G i a proteins when reconstitutheir existence was recognized. Originally, studies of this ted in phospholipid vesicles (413). In transfected GH 4 C 1 subject were carried out in preparations from brain or in cells, D 1 receptors interact with an inhibitory G i a/G o a prosome cases using purified reconstituted receptors. How-tein that has not been better identified (229). In addition, ever, since DA receptor cloning, their coupling properties immunoprecipitation with antibodies specific for different have been studied predominantly in cell lines transfected G protein subtypes revealed that the D 1 receptor coprewith each receptor cDNA. This gave the advantage of cipitates with both G o a (230) and G q a (459) , the latter working with a pure population of receptor, whereas most coupling D 1 receptors to phosphoinositide metabolism brain regions express multiple DA receptor subtypes. (459, 477) . However, heterologous expression systems have the disThat the D 2 receptor can inhibit AC was shown in advantage of mostly being fibroblast in nature, whereas the early 1980s in the pituitary (99, 121, 289, 345) and in the DA receptors are endogenously expressed primarily in the CNS (344). As expected, the cloning of the D 2 receptor neuronal cells. This raises the possibility of the receptors confirmed these observations (reviewed in Ref. 159). being expressed in an environment that may contain difAlthough not immediately apparent, the D 3 receptor ferent complements of G proteins, effectors, and other has been shown to be coupled to inhibition of AC. Initially, molecules than they are in vivo. As a result, the use of it was reported that this receptor did not inhibit AC in different heterologous expression systems has often led cell lines and did not couple to G proteins as shown by to apparently conflicting results.
the lack of a guanine nucleotide shift of agonist binding curves (420). Similarly, subsequent observations also indicated that the D 3 receptor did not inhibit cAMP accumula-A. Adenylyl Cyclase tion in various cell lines (144, 274, 438) . However, more recently it has been shown that the D 3 receptor does As early as the 1970s, it was recognized that DA receptors could influence the activity of AC (reviewed in weakly inhibit AC in some cell lines (75, 287, 360, 377 287, 290, 438) . Thus inhibias striatum, nucleus accumbens, and olfactory tubercle (299). After the cloning of the D 1 receptor in 1990, it was tion of AC seems to be a general property of the D 2 -like receptors. possible to examine its signaling properties in transfected cell lines. In a variety of cell culture lines, it was shown that the D 1 receptor robustly stimulated cAMP accumula-B. Calcium Channels tion (95, 314, 480) . Upon the cloning of the second D 1 -like receptor, the D 5 was also found to be coupled to stimulation of AC, as was predicted from its structural The D 1 -like receptors appear to modulate intracellular calcium levels by a variety of mechanisms. One mechasimilarity to the D 1 receptor (169, 431, 441, 464) . Interestingly, the D 5 receptor appears to exhibit an increased ago-nism is via the stimulation of phosphatidylinositol (PI) hydrolysis by phospholipase C (PLC), resulting in the pronist-independent activity when compared with the D 1 receptor in 293 cells (440) 4 receptors have only been shown to inhibit calcium curincreasing cAMP levels (263) , and thus is probably the result of activation of protein kinase A (PKA).
rents. Finally, the D 1 receptor appears to affect the activity of calcium channels. In both rat striatal neurons and D 1 C. Potassium Channels receptor-transfected GH 4 C 1 cells, D 1 agonists increase calcium currents by L-type calcium channels. In both cases, the effect is mimicked by cAMP analogs (266, 432) and Dopamine receptors have been shown to influence the activity of potassium channels. This has not been well blocked by PKA inhibitors (432) , suggesting that it may be the result of phosphorylation of calcium channels by documented in the case of the D 1 -like receptors. D 1 -like agonists were shown to increase potassium efflux from PKA. In addition, in rat striatal neurons, D 1 agonists reduce calcium currents carried by N-and P-type calcium chick retinal cells via a cAMP-independent mechanism (243) . In contrast, a D 1 -like agonist inhibited a potassium channels. This activity of the D 1 receptor was also mimicked by cAMP analogs and blocked by PKA inhibitors as current in rat striatal neurons (232) .
The role of D 2 -like receptors in modulating potassium well as the phosphatase inhibitor okadaic acid (432) . The proposed model is that D 1 receptors reduce these currents currents has been more extensively studied. In many preparations, it has been shown that D 2 -like receptors increase by PKA stimulation of a phosphatase which, in turn, dephosphorylates the channels leading to their inactivation. outward potassium currents, leading to cell hyperpolarization. Such effects have been observed in rat striatal and Thus the regulation of calcium by D 1 -like receptors appears to be quite complex and occurs through a variety mesencephalic neurons as well as in anterior pituitary (65, 119, 172, 232, 264, 467 The Na / -K / -ATPase, which pumps sodium out of Although Piomelli et al. (356) observed an enhancement of cells and potassium in, is essential for maintaining the the D 2 receptor potentiation of AA release in the presence electrochemical gradient that is responsible for the excitof a cAMP analog, PKC seems more likely to play a role ability of nerve and muscle cells and drives the transport in this signaling system. Downregulation of PKC by 24-h of fluid and solutes across epithelial membranes. It has treatment of cells with phorbol 12-myristate 13-acetate been known that DA receptors influence the activity of blocks the D 2 and D 4 effect (74, 225) as does treatment this ion pump. In this manner, DA regulates fluid absorpwith the PKC inhibitor staurosporine (125) . In addition, tion in the kidney and neuronal excitability in the brain. activation of PKC increases the maximal AA release in Most work has suggested that DA effects on the Na / -K / -the presence of D 2 agonists and calcium ionophore and ATPase are mediated through the D 1 receptor. However, increases the potency of agonist to elicit this response some reports also suggested that activation of both D 1 (109) . This evidence suggests that potentiation of AA re-and D 2 receptors may be required. In a preparation of lease is mediated by alterations in PKC activity. nists have no effect (70, 407). In the kidney, the effects of DA receptor activation on Na / -K / -ATPase activity ap-E. Na " /H " Exchange pear to be the result of phosphorylation cascades involving both PKA and PKC. However, in Ltk 0 fibroblast cells Dopamine receptors also appear to affect the activity of amiloride-sensitive Na 12-16-97 10:23:51 pra APS-Phys Rev Na / -K / -ATPase activity in a PKA-dependent manner (195) . Therefore, although in general it appears that D 1 receptors are responsible for regulation of the Na / -K / -ATPase, the mechanism may vary according to the tissue examined.
G. Additional Signal Transduction Pathways Involved in Mitogenesis
Recent evidence has suggested that in some cases D 2 -like receptors are involved in mitogenesis and cell differentiation. The effect is blocked by PTX and appears to be independent cyclase; PLC, phospholipase C. of alterations in cAMP levels. Lajiness et al. (244) found that the D 2 mitogenic effect was accompanied by an increase in tyrosine phosphorylation levels and was blocked entiation pathways ( Fig. 2 ). However, in many cases, there is conflicting evidence in the literature for the modulation by the tyrosine kinase inhibitor genistein, suggesting that this receptor may cause the activation of the mitogen-of various messengers, or the mechanism by which an effector is modulated by the DA receptors. Many of these activated protein kinase pathway.
In contrast to the above results, the D 2 receptor has discrepancies probably arise from the use of different tissues or cell culture lines. It is now known that many also been shown to inhibit cell growth in some cell lines. (138) found that this effect was abolished by PTX, effectors, and that these have differing patterns of expression and regulatory properties. Defining which of these was accompanied by an increase in phosphotyrosine phosphatase (PTP) activity, and was blocked by the PTP specific signal transduction events is involved in the various physiological actions of DA may require the developinhibitor vanadate. In contrast, another study found that in GH 4 C 1 , the D 2 receptor-mediated inhibition of [ 3 H]thy-ment of specific pharmacological agents or genetic animals models. midine uptake was not blocked by PTX but was blocked by downregulation of PKC and by PKC inhibitors (406) . Thus, although the mechanism of inhibition of mitogen-VIII. DOPAMINE RECEPTORS IN THE BRAIN esis by D 2 receptors in GH 4 C 1 cells is not clear, it may result from PKC-mediated activation of a phosphatase. The effects of D 2 receptor activation on cell growth appear A. Distribution of Dopamine Receptors to highly depend on the cell type examined.
Finally, the D 2 -like receptors may promote some asDopaminergic neurons in the substantia nigra pars compacta, the ventral tegmental area, and the hypothalapects of cell differentiation. When D 2 , D 3 , or D 4 receptors were expressed in the mesencephalic cell line MN9D, ago-mus give origin to three main pathways, the nigrostriatal, the mesolimbocortical, and the tuberoinfundibular. Benists caused increases in neurite number and length as well as total neuritic extent (435) . However, in a study cause of the lack of ligands specific for each receptor subtype, in situ hybridization has been extensively used using primary cultures of rat mesencephalon neurons, a D 2 -like receptor agonist did not affect survival or differen-to study the distribution of DA receptor mRNAs in the brain. tiation of these cells (449) . The role of D 2 -like receptors in neuronal differentiation thus remains to be clarified.
The D 1 receptor is the most widespread DA receptor and is expressed at higher levels than any other DA recepIn conclusion, much effort has gone into studying the signal transduction of the DA receptors during the last 20 tor (95, 145, 463 ). D 1 mRNA has been found in the striatum, the nucleus accumbens, and the olfactory tubercle. years. Many second messengers for these receptors have been identified, including cAMP, calcium, potassium, and In addition, D 1 receptors have been detected in the limbic system, hypothalamus, and thalamus. On the other hand, AA. In addition, these receptors modulate other ''effectors'' by more indirect means, including Na / /H / ex-in other areas where the D 1 receptor protein is highly expressed such as the entopeducular nucleus and the subchangers, the Na / -K / -ATPase, and cell growth and differ-
12-16-97 10:23:51 pra APS-Phys Rev stantia nigra pars reticulata (153, 255), no mRNA has been The D 2 receptor has been found mainly in the striatum, in the olfactory tubercle, in the core of nucleus acdetected (95, 145, 463) . This suggests that in these areas the D 1 receptor is mainly present in projections (95, 145 , cumbens (38; reviewed in Ref. 217) , where it is expressed by GABAergic neurons coexpressing enkephalins (253, 463) . As a matter of fact, D 1 receptors in the entopeduncular nucleus and in the substantia nigra pars reticulata are 256), and in the septal pole of the shell of the nucleus accumbens where it is expressed by neurotensin-conpreferentially localized on striatal GABAergic neurons coexpressing substance P (153, 255) .
taining neurons (105). D 2 receptor mRNA is also present in the prefrontal, cingulate, temporal, and enthorinal corThe D 5 receptor is poorly expressed in rat brain when compared with the D 1 receptor. A distribution restricted tex, in the septal region, in the amygdala, and in the granule cells of the hippocampal formation (38; reviewed in to the hippocampus, the lateral mamillary nucleus, and the parafascicular nucleus of the thalamus, where the D 1 Ref. 217) . It is also found in the hypothalamus, in the substantia nigra pars compacta, and in the ventral tegmenreceptor is not significantly expressed, was originally reported (293, 441) , with little or no message detected in tal area, where it is expressed by dopaminergic neurons (38, 292, 463) . Immunohistochemical analysis with spethe dorsal striatum, nucleus accumbens, and olfactory tubercle. Upon further examination, D 5 receptor mRNA has cific antibodies revealed that D 2 receptors are present in medium spiny neurons of the striatum where they are been found in several rostral forebrain regions including cerebral cortex, lateral thalamus, diagonal band area, stri-more concentrated in spiny dendrites and spine heads than in the somata. Colocalization with D 1 receptors is atum, and, to a lesser extent, substantia nigra, medial thalamus, and hippocampus (76, 203, 366) .
rare. D 2 immunoreactive terminals are frequently detectable, forming symmetrical, rather than asymmetrical, synThe development of specific antibodies against DA receptor subtypes recently made it possible to define their apses (187, 260). The D 2 receptors are present in perikarya and dendrites within the substantia nigra pars compacta cellular and subcellular localization in different regions of primate brain. Both D 1 and D 5 receptors are coex-and are much more concentrated in the external segment of the globus pallidus than in other striatal projections pressed in pyramidal neurons of prefrontal, premotor, cingulate and entorhinal cortex, the hippocampus, and the (260). D 2 receptor immunoreactivity has been detected in the glomerular and internal plexiform layers of the olfacdentate gyrus (27, 28, 197, 417) . Electron microscopy analysis demonstrated that in the prefrontal cortex and the tory nerve and in the central nucleus of the amygdala (260). hippocampus, D 1 and D 5 receptors have both pre-and postsynaptic localization, with the postsynaptic one more The D 3 receptor has a specific distribution to limbic areas (245, 246) such as the ventromedial shell of the frequently observed. Ultrastructural analysis suggested that within individual pyramidal neurons, D 1 and D 5 recep-nucleus accumbens (38) where it is expressed by substance P and neurotensin neurons projecting to the ventors have a different localization with the D 1 concentrated in dentritic spines and the D 5 in dendritic shafts (28, 417). tral pallidum (105, 106) , the olfactory tubercle, and the islands of Calleja (38, 258). In contrast, it is poorly exIn the olfactor bulb D 1 receptors are restricted to the internal granular and plexiform layers and in the amygdala pressed in the dorsal striatum (38, 258, 420). The D 3 mRNA was also found in the substantia nigra pars comin the intercalated and basolateral nuclei (260). In the caudate nucleus, D 1 and D 5 receptors are mostly localized pacta, in the ventral tegmental area, where it is expressed in a minority of dopaminergic neurons when compared within medium-sized GABAergic neurons (28, 197, 417 ). D 5 but not D 1 receptors are present also in large choliner-with the D 2 receptors and in the cerebellum (105, 106) .
In the islands of Calleja, both D 3 receptor binding and gic interneurons (28). Ultrastructural analysis suggested that D 1 receptors are present on spines postsynaptic to mRNA are present in granule cells (106, 258) , which are known to make sparse contacts with dopaminergic axasymmetrical synapses, that both D 1 and D 5 receptors are at postsynaptic densities of small synapses characteristics ons. Purkinje cells in lobules 9 and 10 of the archicerebellum express D 3 mRNA, whereas binding sites were deof DA terminals, and that presynaptic D 1 and D 5 receptors are on axons forming asymmetrical synapses (28, 187, 260, tectable only in the molecular layer (106, 258) . No dopaminergic projections are present in this area, suggesting 417). D 1 receptors have been localized in the entopeduncular nucleus and in the pars reticulata of the substantia that the D 3 receptor may respond to DA diffusing extrasynaptically (106) . The D 3 receptor was also found at nigra, where D 5 receptors are undetectable (28, 187, 260). This observation suggests that if D 1 and D 5 receptors are low expression levels in the hippocampus, in the septal area, and in various cortical layers and subregions of the colocalized in medium-sized spiny neurons of caudate, only the D 1 receptor is transported to striatonigral termi-medial-temporal lobe (38).
Low levels of the D 4 receptor mRNA have been found nals. These differences in the cellular and subcellular localization thus suggest that although D 1 and D 5 receptors in the basal ganglia. In contrast, this receptor appears to be highly expressed in the frontal cortex, amygdala, exhibit similar pharmacology, they are not functionally redundant.
hippocampus, hypothalamus, and mesencephalon (343, Although some inconsistencies are present in the littial for D 2 agonists to produce maximal locomotor stimulation (41, 116; reviewed in Refs. 79, 217, 456, 457) . As erature, there is a general agreement that mesolimbocortical DA plays a role in learning and memory. In the mondiscussed in section VIII D, these pharmacological observations have been explicitly confirmed by targeted inactiva-key, DA neurons in the A10 area have been reported to be involved with transient changes of impulsive activity tion of the D 1 receptor gene in the mouse (471, 472) . The D 3 receptor, which has been shown to be mainly in basic attention and motivational processes underlying learning and cognitive behavior (394) . Pharmacological postsynaptically located in the nucleus accumbens (106), seems to play an inhibitory role on locomotion. D 3 The role of D 3 and D 4 receptors in the physiology of pears to produce a synergistic effect on c-fos expression (242) . Separate administration of selective D 1 or D 2 agodopaminergic system is still mostly unknown. They are specifically expressed in limbic and cortical regions in-nists induces an increase of Fos immunoreactivity in few neurons, whereas combined administration of D 1 and D 2 volved in the control of cognition and emotion and, to a lesser extent in the dorsal striatum, and this makes them agonists produced patches of intensely stained immunoreactive nuclei in the striatum (350) . In line with this, adminattractive and promising targets for new generations of antipsychotic drugs with low incidence of extrapyramidal istration of SKF-38393 to DA-depleted rats increased the striatal expression of c-fos, whereas quinpirole did not side effects.
significantly modify it (227). Combined administration of SKF-38393 and quinpirole, however, produced a higher C. Dopamine Receptors and Regulation extent of c-fos expression than SKF-38393 alone (227).
of Gene Expression
Moreover, amphetamine and cocaine, which increase DA overflow, appear to be more effective in inducing c-fos The study of receptor and peptide levels in the stria-expression than receptor-selective direct agonists. tum after perturbation of DA transmission has been useful These findings are in line with behavioral and electroin better understanding the organization and regulation physiological evidence suggesting the existence of D 1 and of the dopaminergic system. The paradigms used in these D 2 synergism in the striatum (79, 116, 242, 375, 455) . Howapproaches have included consequences of blockade of ever, the anatomic basis of this synergism is still a matter DA receptors (as occurring after neuroleptic treatment), of debate. interruption of dopaminergic transmission (as occurring in Parkinson's disease), or after the hyperactivation of 2. Neuropeptides the DA system (observed after abuse of psychostimulants such as cocaine and amphetamine). Activation of DA reAnatomic, pharmacological, and molecular studies ceptors results in fact in modulation of both peptide and have given some insights in the mechanisms underlying immediate early gene expression. On the other hand, ex-D 1 /D 2 synergism. Striatal efferent neurons are known to pression of the genes encoding DA receptors is subject be under the influence of DA. As shown in Figure 3 One population projects to the entopeduncular nucleus and Fos is the protein product of the immediate-early gene c-fos and is considered to be a marker of some neu-the substantia nigra pars reticulata (striatonigral) and expresses the neuropeptides substance P (SP) and dynorronal activities. Fos appears to be required for long-lasting modifications of gene expression in response to acute phin (Dyn) (152, 255). The other projects to the external segment of the globus pallidus (striatopallidal) and constimuli and has been shown to be one of the final targets in the signaling cascade of DA receptors (374). Basal tains enkephalin (152, 256). The striatonigral neurons preferentially express D 1 receptors that mediate the stimc-fos expression in the striatum is very low. However, administration of caffeine (322) , haloperidol (330, 372), ulatory effects of DA on SP and Dyn expression (153, 255), whereas the striatopallidal neurons mainly express raclopride (102), cocaine, and amphetamine (171, 193, 213, 330) remarkably stimulates c-fos expression in the D 2 receptors, inhibiting the expression of preproenkephalin A (PPA) (Fig. 3) (153, 256) . A similar receptor organizaventral and dorsal striatum with regional and cellular specificity depending on the drug used. Therefore, it has tion was found in the nucleus accumbens with D 1 receptors mostly expressed in SP neurons (253), D 2 in enkephabeen proposed that Fos and Fos-related antigens may be used to map specific pathways involved in the response lin and neurotensin neurons (253) , and D 3 receptors in SP and neurotensin neurons (105, 106) . to modifications of the neuronal environment. Retrograde tracing studies suggested that cocaine and amphetamine
In the ventral shell of the nucleus accumbens, D 3 recep-
12-16-97 10:23:51 pra APS-Phys Rev In line with these observations, pharmacological served at molecular, electrophysiological, and behavioral levels may occur by interneuronal interactions. A D 2 -medistudies have shown that DA agonists and antagonists as well as disruption of dopaminergic transmission by either ated suppression of striatopallidal neurons might in fact relieve a tonic inhibitory influence of enkephalin or GABA 6-hydroxydopamine (6-OHDA) or reserpine modulate striatal peptide gene expression in a way that confirms the on striatonigral neurons, thus increasing D 3 receptors have been shown to be regulated oppo-level, SP mRNA was decreased in mutant mice, whereas PPA mRNA levels were unchanged (114) . These molecular site from the D 2 receptors. Denervation leads to D 3 receptor downregulation. This paradoxical effect seems to be changes demonstrate that these mice exhibit selective functional changes in striatal neurons with a direct output unrelated to deprivation of either DA or one of its cotransmitters and has been proposed to be dependent on a yet pathway to the substantia nigra.
Inactivation On the basis of these results, inactivation of the other trophins have been shown to exert a differentiative and trophic effect on central dopaminergic neurons (22, 61, 62, members of the DA receptor family could provide valuable information about their physiological functions. The 136, 428). These observations suggest that specific factors originating from surrounding cells such as glial cells or drawback of this approach, however, is that inactivation of specific receptor genes in the mouse germ line profrom afferent neurons or by the dopaminergic neurons themselves may regulate DA receptor gene expression duces animal phenotypes where possible developmental alterations and compensatory changes are superimposed during development and adaptation to abnormal stimuli or pharmacological treatments.
on the true effects of receptor removal, so that behavioral
12-16-97 10:23:51 pra APS-Phys Rev alterations in the mutant mice should be interpreted with the mechanism of action of its antipsychotic effects (296, 401). There were recent claims that D 4 receptors, measome caution. Development of spatially and temporally targeted inactivation of specific receptor genes could be sured by indirect binding, may be increased in the brain of schizophrenic patients (402, 400) . Additional work will helpful to overcome this problem and to produce a clearer picture of the function of DA receptors in adult animals be required to confirm these findings, since many of these observations came from indirect measurements with paras opposed to their role in development.
tially selective ligands. The hypothesis that the dopaminergic system is over-1. Genetic linkage of dopamine receptors active in schizophrenia is based on the observation that to pathophysiologies neuroleptics, which are used in the management of the major symptoms of this disorder, selectively block DA
The cloning and characterization of the human genes for the five DA receptors have initiated studies of their receptors (223, 286, 368, 415) . The DA hypothesis was further strengthened by the fact that amphetamine in-genetic relationship with neuropsychiatric disorders associated with the DA system. These include bipolar disorder duces psychotic states resembling those observed in the positive symptoms of schizophrenia (euphoria, auditory (96, 228, 411), schizophrenia (83, 324, 367, 429) , manic depression (220), Parkinson's disease (325) , and Touhallucinations, and akathisia or the inability to remain inactive).
rette's syndrome (151). For all of these conditions, there is strong evidence against linkage of any of the five DA Treatment with neuroleptics has the major drawback that most of patients under medication suffer from ex-receptors. For example, chromosome 11 has long been suspected to harbor a gene causing predisposition to bipotreme movement disorders known as extrapyramidal syndrome. The symptoms include muscular rigidity and aki-lar disorder. It has been extensively studied for genetic linkage with genes coding for tyrosine hydroxylase, tyrosinesia that are sometimes difficult to distinguish from the negative symptoms of schizophrenia. Moreover, pro-nase, and D 2 and D 4 DA receptors, all of which can be found on human chromosome 11 (96, 228, 411) . All studies longed treatment invariably leads to irreversible tardive dyskinesia. It is believed that the antipsychotic effects of conducted to date exclude any possible association between these markers and the pathogenesis of bipolar disneuroleptics are due to their action on the dopaminergic receptors in the mesolimbic system, whereas the extrapy-order at least in the pedigrees examined.
Because the implication of the dopaminergic system ramidal side effects are thought to result from blockade of D 2 receptors in the striatum (reviewed in Refs. 103, in the etiology of schizophrenia is strong, the alleles coding for five DA receptors have been investigated and all 297, 415). From this perspective, the discovery of multiple DA receptors with differential expression in the brain and systematically excluded in many pedigrees including Japanese, Swedish, Italian, Irish Californian, and Amish (83, with different affinities for antipsychotic drugs is of great interest.
324, 367, 429). Crocq et al. (86) , however, detected a small but significant increase in the risk of schizophrenia in two The high overall sequence homology between DA receptors of the same subfamily has made it extremely French and British populations associated with homozygosity at D 3 . These findings, however, need to be conlaborious to develop specific ligands that do not interact with related receptors. Of particular interest is the high firmed. None of the various alleles of the D 4 receptor seems to be associated with an increased risk of schizoaffinity of ''atypical'' neuroleptics, such as sulpiride and its derivatives and clozapine, for D 3 and D 4 receptors, phrenia (273, 312, 325) .
The situation is not clear regarding appetite and adrespectively (154, 399, 420). The low level of expression of the D 3 and D 4 receptors in the striatum and their rela-dictive behaviors such as alcoholism. Indeed, early reports did indicate that the A1 allele of the Taq I restriction tively high expression in limbic and cortical areas led to the suggestion that the antipsychotic actions of neuro-fragment length polymorphism containing the D 2 DA receptor gene may confer susceptibility to alcoholism. This leptics may be mainly mediated through D 3 and D 4 receptors, whereas the side effects may be mediated through claim has proved to be controversial, with three reports confirming the original findings and two others excluding D 2 receptors. This hypothesis is further strengthened by the observation that administration of clozapine is asso-the existence of a possible linkage (reviewed in Refs. 82, 167) . The possibility that a remote regulatory element conciated with a very low incidence of extrapyramidal side effects. However, clozapine at therapeutic doses also trolling the expression of a candidate gene could be involved in the disorder investigated should also be taken blocks many other types of receptors, in addition to the D 4 receptor, so that it is difficult to draw conclusions on into consideration. (269, 270, 447) . All these effects are mediated by of changes in blood flow in response to the administration G proteins, with G o a mostly involved in the inhibition of of catecholaminergic agonists and antagonists. Two discalcium currents and G i-3 a in the activation of voltage-tinct patterns of responsiveness were observed, and these dependent potassium channels (268, 302) .
were classified as DA 1 and DA 2 (reviewed in Ref. 166 ) in In addition, the recent findings that the expression of a scheme that paralleled the D 1 /D 2 classification of Kethe POU/Pit1 transcription factor, which activates growth babian and Calne (226). hormone (GH) and Prl gene expression (210, 454) , is inThe cloning and molecular characterization of DA hibited by activation of D 2 receptors in transfected cell receptors later indicated that the same molecular species lines (120, 262) suggest the existence of a dopaminergic are present in the CNS and in some peripheral tissues. control on Prl gene expression.
The existence of different D 1 -like and D 2 -like receptors in The presence of D 2 receptors inhibiting Prl secretion the cardiovascular system, however, has not been systemin the anterior pituitary leads to a major therapeutic appli-atically investigated. It has been shown that all the cloned cation in the treatment of hyperprolactinemia either due DA receptors are present in the kidney (148, 285, 326, 420, to functional hypothalamus-pituitary defects or to the 473) and that D 4 receptors are present in the heart (343). presence of Prl-secreting tumors. D 2 receptor agonists, However, little is known to date about the molecular nasuch as bromocriptine, are in fact the most effective phar-ture of DA receptors in blood vessels, in postganglionic macological tool to normalize plasma Prl levels in these sympathetic nerve terminals, and in the adrenal cortex, patients (reviewed in Ref. 89) .
so their function and classification in these regions are These observations stimulated the study of D 2 recep-largely based on pharmacological data. The distribution tor pharmacology, biochemistry, and functional proper-and function of peripheral DA receptors are summarized ties as well as the mechanisms regulating its expression in in Table 3 . The physiological role of a direct dopaminergic mech- Heart D 4 Unknown anism in the regulation of renin secretion is still a matter NE, norepinephrine; E, epinephrine.
of controversy. The wide range of activity of DA in the cardiovascular system makes the results of in vivo studies difficult to interpret. The effects of DA on blood pressure, cordings of cardiac contractility, heart rate, arterial blood cardiac output, and regional blood flow distribution may pressure, and renal and femoral blood flows (reviewed in in fact indirectly influence renin secretion.
Ref. 166). The results of these studies led to the current
In vivo studies in conscious and anesthetized dogs paradigm that postjunctional D 1 receptors producing di-have shown that intrarenal infusions of DA either inrect vasodilatation are present in the renal artery and that creases renin secretion, an effect associated with renal prejunctional D 2 receptors on postganglionic sympathetic vasodilatation, or does not affect plasma renin activity nerve terminals inhibit norepinephrine release to indi-(PRA) (reviewed in Ref. 309). In most studies in humans, rectly induce vasodilatation in the femoral artery and de-no consistent effects of intravenous infusion of DA on crease of cardiac contractility (166) .
renin secretion were observed (54, 53, 115, 334, 423). FragSubsequent studies using either radioligand binding mentary observations reported that infusion of low doses combined with autoradiography or measurement of AC of DA or administration of gludopa decreased PRA, activity confirmed and extended the results of physiologi-whereas high, pressor doses of DA increased PRA in cal studies. D 1 receptors associated with stimulation of AC healthy subjects (reviewed in Ref. 309). Administration of have been identified in the renal, mesenteric, and splenic either bromocriptine to normal subjects in sodium balarteries (307) and were shown to be concentrated in the ance (56) or dihydroergotoxine to hypertensive patients medial layer and to be insensitive to chemical sympathec-kept on both normal and low sodium intake (271) does tomy (5), thus confirming their preferential postjunctional not modify PRA. On the other hand, it has been shown localization.
that D 1 agonists can stimulate renin secretion from renal D 2 receptors were shown to be localized in the adven-cortical slices (9, 241) and that D 1 receptors are present titial as well as the adventitial-medial border and intimal on renin-containing vesicles within the juxtaglomerular layer of renal, mesenteric, and splenic arteries (4) and apparatus (336) . Thus the major effect of DA on renin to be associated with inhibition of AC (307). Chemical secretion is stimulatory and is mediated by D 1 receptors. sympathectomy remarkably reduced the density of D 2 receptors in the adventitial and adventitial-medial layers, 2. Dopaminergic mechanisms controlling but not in the intimal layer (4), thus suggesting that both aldosterone production prejunctional and postjunctional D 2 receptors are present in arterial vessels. In addition, chemical sympathectomy
The first evidence for a role of DA in the control of aldosterone secretion came from in vivo studies in both did not modify the extent of inhibition of AC by D 2 agonists, suggesting that postjunctional D 2 receptors are asso-humans and experimental animals.
Administration of the D 2 antagonist metoclopramide ciated with inhibition of cAMP formation, whereas pre-P16-7 / 9j07$$ja09
12-16-97 10:23:51 pra APS-Phys Rev to both rats and humans was shown to increase plasma sterone secretion but did not modify the hormone release under basal conditions or after stimulation by adrenocoraldosterone levels without modifying any of the known stimulators of the hormone release, an effect that was ticotropic hormone (311) . Consistent with this, it has also been shown that activation of D 2 receptors inhibits cAMP blocked by intravenous infusion of DA (56, 334, 422). Administration of DA and of DA agonists such as bromocrip-formation and Ca 2/ influx, both induced by angiotensin II (146, 309). These data thus indicated that the effects of tine, however, did not modify basal plasma aldosterone levels (37, 53, 56, 57, 470). These observations thus sug-DA on aldosterone secretion are mediated by D 2 receptors in adrenal glomerulosa cells and pointed to a selective, gested that aldosterone production is under maximum tonic dopaminergic inhibition.
functional interaction between DA and angiotensin II in the regulation of the production of aldosterone. Subsequent studies confirmed this hypothesis and pointed to the sodium balance state as being crucial for One issue that is still open concerns the origin of DA in this system. In particular, whether D 2 receptors in the effects of exogenous DA on aldosterone secretion. During sodium depletion, DA excretion is decreased, cir-glomerulosa cells are the target of circulating DA or whether a dopaminergic innervation is present in the adreculating aldosterone is increased, and plasma aldosterone responsiveness to angiotensin II is increased (57, 191) . nal cortex is still matter of investigation. No evidence for the presence of dopaminergic terminals in the adrenal Reciprocal findings were reported in the sodium-replete state (2). According to these concepts, it has been shown cortex has been reported so far. However, it has been shown that noradrenergic varicosities surrounding the that the increase in plasma aldosterone levels induced by angiotensin II infusion and by upright posture was zona glomerulosa are able to accumulate DA from the circulation and to release it in response to neural activity remarkably inhibited by both DA and D 2 agonists in normal subjects in metabolic balance at low sodium intake, or to convert it into norepinephrine (358, 453) , thus providing the possibility of a fine tuning of local circulation but not in sodium-repleted subjects (58, 115, 276). Similarly, the D 2 agonist dihydroergotoxine remarkably re-and glomerulosa cell activity. duced plasma aldosterone levels in hypertensive patients kept on a low-sodium diet ( Studies with radiolabeled ligands did not reveal the cortical glomeruli (23, 110), and neural input appears to be important for regulation of the renal hemodynamic presence of D 1 receptors in the adrenal medulla. However, the development of fluorescent ligands for DA receptors responses to volume expansion with saline (185) . Dopamine formed within the renal tubular epithelium also acts made it possible to prove the previously unappreciated existence of D 1 receptors in adrenal chromaffin cells by as an intrarenal paracrine or autocrine hormone to regulate the reabsorption of sodium ions within the nephron fluorescence microscopy (14). Stimulation of these receptors activates the facilitation 27-pS dihydropyridine-sensi-(24, 130, 198, 222, 247, 249) . Furthermore, D 1 dopaminergic agonists stimulate the secretion of renin (9, 241), and tive calcium channels in the absence of predepolarizations or repetitive activity (14). Facilitation calcium channels interactions of dopaminergic signal transduction with signaling by other renal hormones such as angiotensin II in unstimulated bovine chromaffin cells are normally quiescent and are activated by large predepolarizations or (71), atrial natriuretic peptide (182, 462), and antidiuretic hormone (321) have been described. by repetitive depolarizations, such as increased nerve splanchnic activity. This activation resulting in a twofold Interestingly, some patients with hypertension and animal models of essential hypertension exhibit abnormal increase in calcium current suggests a physiological role for these channels in stimulating rapid catecholamine se-dopaminergic responses to saline loading or inefficient dopaminergic signal transduction through renal DA recepcretion in response to danger or stress (14). The recruitment of these channels by D 1 receptor stimulation may tors. It is possible that molecular characterization of the DA receptor subtypes and mechanisms of dopaminergic thus be the basis of a positive-feedback loop mechanism for catecholamine secretion mediated by DA (14) .
signal transduction within the kidney will lead to the identification of potential targets for new antihypertensive In conclusion, DA seems to have a dual effect on catecholamine release, a tonic inhibitory activity medi-agents. (284) and selective ligands are higher in homogenates of renal tissue than in membrane preparations from the brain (412). phosphate (88, 97, 163, 211, 224 ) excretion by DA have also been described, the bulk of recent investigations have However, the dissociation constants for binding of D 1 -selective ligands to the opossum kidney (OK) cell D 1 refocused on the regulation of sodium homeostasis, and the effects of renal dopaminergic regulation of sodium ceptor are higher when the receptor is expressed endogenously in OK cell membranes than when the receptor is handling have been found to be most pronounced under conditions of mild sodium excess (46, 72, 177, 363) .
transfected into COS cells, although comparison reveals a linear relationship between the two data sets (20, 326). Intravascular administration of DA causes increases in renal blood flow and in sodium and water excretion in This suggests that some factor independent of the primary sequence of the protein might be responsible for the lower human subjects (2, 87, 164, 288) and experimental animals (19, 291, 353). At low doses, which do not affect systemic affinities of drugs for renal receptors.
Adenylate cyclase is stimulated by DA or dopaminerhemodynamics, DA produces renal vasodilation, diuresis, and natriuresis (50, 300), and these effects have led to the gic agonists in renal preparations (124, 410) with an order of agonist potency that resembles the DA-stimulated AC clinical use of low-dose DA infusion in certain pathological conditions (165, 251, 364) . Either high dietary salt in-in striatal membranes, although the efficacy of all agonists appears to be reduced two-to fivefold in renal membranes take or volume expansion with normal saline causes a rise in urinary excretion of DA with a concomitant natri-in comparison with brain preparations (130) . Dopamine and D 1 -specific agonists also stimulate PI hydrolysis in uresis and diuresis (183, 335) that can be blocked by administration of dopaminergic antagonists (143, 237) .
proximal tubules by a cAMP-independent mechanism (124, 126) . Both the human and goldfish D 1 receptors have Within the kidney, DA is formed in renal nerves and in the epithelial cells of certain nephron regions. Dopa-been found to increase intracellular calcium when expressed in HEK 293 cells by a cAMP-dependent mechaminergic nerve endings have been detected in proximity to the vascular pole/juxtaglomerular apparatus of renal nism (263) .
12-16-97 10:23:51 pra APS-Phys Rev B) D 2 -LIKE RECEPTORS. Radioligand binding identified ence of the D 1 receptors in rat glomeruli (336) . On the other hand, primary cultures of rat glomerular mesangial high-affinity and low-affinity haloperidol binding sites in homogenates of renal cortex and high-affinity spiroperidol cells express a D 1 -like receptor that has been well characterized pharmacologically (43, 44). sites in purified proximal tubule cells. The high-affinity site shows a pharmacological profile very similar to cen-B) PROXIMAL TUBULE. The proximal tubule is the site of reabsorption for two-thirds of the water and sodium tral D 2 receptors (21, 127, 323). Radioligand autoradiography of rat renal slices with [ 3 H]spiperone has been used present in the glomerular filtrate as well as for virtually all important metabolic products (e.g., amino acids and to characterize a D 2 -like receptor that has been termed the D 2K (207) . The pharmacological profile of this receptor glucose) (279, 382) . Membranes prepared from isolated proximal tubules contain both D 1 -like and D 2 -like recepappears unique to the kidney; however, there are insufficient data for a satisfactory comparison with the cloned tors (127) . Thus the proximal tubule is likely to play an important role in the natriuretic and diuretic responses D 3 and D 4 receptors (401) .
Dopamine inhibits AC in isolated glomeruli (129) and to renal DA. The proximal tubule also is the major site of DA synrat renal cortical membranes (369) . In inner medullary collecting duct cells, the putative D 2K receptor has been thesis within the kidney due to a high concentration of Laromatic amino acid decarboxylase at the apical pole of linked to the production of prostaglandin (PG) E 2 by phospholipase A 2 and to the mobilization of intracellular cal-the tubular epithelium (33). The vast majority of urinary DA is derived from L-dopa that is decarboxylated at this cium via a PTX-sensitive G protein (204, 206) .
epithelial site (481) . The regulation of intrarenal DA synthesis is still not well understood; however, plasma so-2. Dopaminergic sites of action within the kidney dium concentration is thought to act at several levels to increase the effective concentration of DA (reviewed in A) GLOMERULUS. At the vascular pole of the glomerulus, DA has been shown to exert a dose-dependent relax-Ref. 419). First, the uptake of L-dopa is sodium dependent; thus higher sodium concentrations yield a higher rate of ation of both efferent and afferent glomerular arterioles (117) that is mimicked by D 1 agonists fenoldopam or SKF-substrate delivery (419). Additionally, an increase in sodium concentration inhibits the oxidation/inactivation of 87516 and blocked by a D 1 antagonist (118) . In the rat, DA released from intrarenal nerve endings plays a role in DA by monoamine oxidases in tissues slices (419). In the intact animal, however, a simple increase in the concenthe increased glomerular filtration rate that is part of the dopaminergic response to volume expansion with saline tration of sodium within the renal tubules is not sufficient to trigger the dopaminergic response associated with inor increased dietary intake of salt (16). Although the importance of dopaminergic neurotransmission is contro-creased dietary salt intake or volume expansion with isotonic saline (184). versial (40, 107), DA has been shown to regulate the release of norepinephrine through D 2 receptors located on Tubular DA acts to inhibit the reabsorption of sodium within the proximal tubule and possibly at more distal nerve endings (381). Dopamine receptors within the vascular elements adjacent to the renal glomeruli, or D 1 -like sites along the nephron (202, 382) . Dopamine inhibits the apical Na / /H / antiporter in proximal tubule cells (156) receptors in mesangial cells, may be at least in part responsible for DA-induced changes in glomerular filtration via activation of D 1 -like receptors (218) by both cAMPdependent (125) and cAMP-independent (123) mecharate.
D 1 -like receptors have been identified within the jux-nisms. This protein is responsible for the vast majority of sodium uptake from the glomerular filtrate. Additionally, taglomerular apparatus by the ability of fenoldopam to stimulate the secretion of renin from renal cortical tissue the reuptake of sodium is dependent on the maintenance of a gradient in sodium concentration across the cellular slices (9, 241). Electron microscopic immunocytochemical experiments have recently demonstrated the presence membrane that is produced by the action of Na / -K / -ATPase located on the basolateral membrane of the epithelial of D 1 receptors on renin-containing granules within the juxtaglomerular apparatus (336) .
cell. Dopamine has been found to inhibit the action of Na (199, 437) , but not others (131, 205) , using isolated proximal tubules, DA inhibition of Na / -K / -ATPase was shown to be dependent on activation of PKC report the presence of specific binding within the glomeruli. Immunohistochemistry also failed to detect the pres- (36, 388) . In vitro studies demonstrate that phosphoryla-P16-7 / 9j07$$ja09
12-16-97 10:23:51 pra APS-Phys Rev tion of the catalytic subunit of Na / -K / -ATPase with either treatment with fenoldopam (339). The antagonism of vasopressin signaling observed physiologically is hypothe-PKA or PKC is sufficient to inhibit pump activity (32, 195) . However, within the proximal tubule, PKA does not ap-sized to involve D 2 -like receptors (339). The intramedullary collecting duct has been demonstrated to express the pear to be responsible for Na / -K / -ATPase inhibition (388). Furthermore, the straightforward mechanism of a direct so-called D 2K receptor (204, 206, 207) . The specific role of this receptor in the dopaminergic control of renal function interaction of Na / -K / -ATPase with PKC leading to an inhibition of the pump does not readily account for the re-remains unclear, although PGE 2 is an inhibitor of sodium transport (181) and of Na (236, 321) is also thought to occur in the distal nephron. The mechanism of this ligands (most notably with SCH-23390) in renal cortical membranes (131, 200, 205) or kidney-derived cell lines effect is unclear, but no inhibition of the vasopressinstimulated AC was observed in microdissected CCD after (20), and the lower affinity site has been suggested to P16-7 / 9j07$$ja09
12-16-97 10:23:51 pra APS-Phys Rev potentially represent an unidentified subtype (20, 198) . from these animals revealed a decreased ability of dopaminergic agonists to stimulate production of cAMP (340) This lower affinity site has been demonstrated, however, to lack stereoselectivity and most likely represents bind-and a loss of the dopaminergic regulation of Na / -K / -ATPase (331, 332) . ing to a nonreceptor site (192) . With respect to potential novel D 2 -like subtypes, a fair argument can be made that
In contrast, 4-wk-old SHR have higher urinary DA levels than control rats (475) , and maintenance on a highthe D 2K binding site described in inner medullary collecting duct is pharmacologically different from the cloned salt diet increased DA production in a manner similar to the response of some groups of essential hypertension D 2 receptor (204, 206, 207) . However, insufficient data are available to allow a satisfactory comparison of the D 2K patients (238, 239, 408 (238) . Although normal subjects demonstrate a affinity labeling (446) . The loss of high-affinity agonist rise in urinary DA excretion after salt loading (335), some binding suggests a defect in G protein coupling that is hypertensive patients display a paradoxical fall in urinary reinforced by the observation that coadministration of G DA excretion (180). Furthermore, some hypertensive paprotein activators (e.g., NaF) and fenoldopam yields a tients have been shown to respond with an exaggerated synergistic inhibition of angiotensin II-induced vasoconlevel of natriuresis and diuresis to the administration of striction (68). (208, 384, 409) .
is also impaired (69). Investigation of the effect of cholera and PTXs on DA inhibition of Na / -K / -ATPase in SHR dem-B. Animal Models of Hypertension onstrated that this effect could be partially recovered after treatment of proximal tubule preparation with PTX (176). Interestingly, the regulation of sodium-coupled phosphate Two rat models of genetic hypertension, the Dahl salt-sensitive strain and the spontaneously hypertensive transport appears to function normally in these animals (98) . Amplification of a region of the D 1 gene by PCR from rat (SHR) Okamoto-Aoki strain, display abnormalities in renal DA production or signal transduction (133, 221, 239) . the genomic DNA of SHR revealed no mutations within the third intracellular loop, a region which is important for G After introduction of a high-salt diet, DA production decreased in the Dahl strain (100, 239, 474) reminiscent of protein coupling, although other receptor regions were not examined (473) . Defects may also be present in downthe response of low renin essential hypertension patients (239) . The Dahl strain also shows an impaired natriuretic stream components of the dopaminergic signal transduction pathway, since the Na / /H / exchange activity within and diuretic response to volume expansion with isotonic saline (385). Examination of isolated proximal tubules the proximal tubule was inhibited by exogenously added P16-7 / 9j07$$ja09
12-16-97 10:23:51 pra APS-Phys Rev 8-chlorophenylthio-cAMP in 3-to 4-wk old rats, but this There are indications that the diversity in DA recepinhibition was lost in adults (194) .
tors will not be limited to the five subtypes already characAlthough it is not at all clear that the underlying de-terized. Biochemical, pharmacological, and molecular fects in these animal models correspond to those underly-studies suggested the existence of further heterogeneity ing human pathology, it would seem clear that the study within D 2 receptors in the pituitary. Although the majority of DA receptors and dopaminergic signal transduction in of DA agonists can activate with the same efficiency both the kidney holds the promise of providing a better under-inhibition of AC and opening of potassium channels in standing of the pathophysiology of human hypertension pituitary lactotrophs (65, 212, 269, 270, 298) , the benzazeand will perhaps also lead to the identification of new pine derivative BHT-920 does not inhibit cAMP formation, molecular targets for therapeutic intervention and new while activating potassium channels (357) . This observapharmacological agents.
tion may suggest that two distinct D 2 -like receptor subIn conclusion, the distribution and function of recep-types may exist with different affinities for BHT-920 and tors for DA within the cardiovascular system is such that be individually coupled to one or the other signaling path-DA agonists, by acting at different levels, may induce way. Consistent with this idea are the results of binding changes that synergistically operate to reduce blood pres-studies in the anterior pituitary and in the striatum, unravsure, thus making them the potential target for a new class eling the existence of an extra D 2 site with low affinity of antihypertensive drugs. In particular, the dilatation of for spiperone (398) and in GH 3 cells that express a D 2 -splanchnic vascular beds, the reduction of circulating cat-like receptor with an unusual low affinity for haloperidol echolamines, the inhibition of norepinephrine release at in response to NGF (305). Similarly, studies with the kidsynaptic terminals, the inhibition of stimulated aldoste-ney pointed to the existence of a unique renal D 2 -like rone secretion, and the increase of sodium excretion are receptor (D 2K ) and suggested the existence of heterogeneinvolved in the hypotensive effects of DA.
ity within D 1 -like receptors as well. Similarly, the property of DA of reducing afterload Behavioral studies also suggested the existence of through D 1 receptor-mediated vasodilatation, of increas-D 1 -like receptors that either display unique affinities for ing renal blood flow and improving renal function, and some D 1 -selective compounds or are not defined as AC of decreasing aldosterone secretion and norepinephrine coupled (13, 94, 113, 301). In addition, evidence showing release together with its positive inotropic effect provide differential order of potencies and efficacies for a series beneficial hemodynamic effects that have potential appli-of benzazepine compounds in stimulating phosphoinosications in the treatment of congestive heart failure (165) . tide hydrolysis and in activating AC in brain tissues suggests that the D 1 receptor that is linked to PLC differs XII. CONCLUDING REMARKS from that coupled to AC (445) . In line with this, it has been shown that when rat striatal mRNA is fractionated The development of the recombinant DNA technolo-and then expressed in Xenopus oocytes, the mRNA fracgies made it possible to identify new DA receptor subtypes tion that demonstrates a PLC-coupled DA receptor is and provided valuable information about the structure of prominently different in size from AC-coupled D 1 recepthe receptor proteins. The use of site-directed mutagene-tor mRNA (275) . The recent cloning and characterization sis and receptor chimeras allowed us to find the determi-of a novel D 1 -like receptor subtype, named D 1C , from nants of ligand binding and of coupling to specific G pro-Xenopus laevis (430) and of another unique subtype, teins. The use of PCR and in situ hybridization with the named D 1D , from Gallus domesticus (101) may hint to cloned DA receptor probes made it possible to define the the existence of a further heterogeneity within mammalocalization of DA receptor subtypes even in brain areas lian D 1 -like receptors. where they were undetectable with more classical methIn spite of this evidence, however, cloning by homolods. The progress made in the study of signal transduction ogy has not identified any new DA receptor in mammals has played a critical role in providing a molecular basis since 1991. However, the possibility should not be exto understand how activation of DA receptors translates cluded that, as is the case for other neurotransmitters, in changes in neuronal and peripheral cell function. On DA receptors structurally divergent from the ones that the other hand, two major issues are still open: 1) pharma-have been already cloned still remain to be identified and cological agents selective for each receptor subtype are characterized. not yet available, and 2) the physiological function of the newly cloned DA receptor subtypes is still mostly 
